August 19, 2021
Wakamoto Pharmaceutical said on August 18 that it has granted US and Canadian rights to exclusively develop and commercialize its ophthalmic surgical drug MaQaid (triamcinolone acetonide) to American ophthalmology specialist Harrow Health. MaQaid, licensed as MAQ-100, is an ophthalmic injection...read more